Kiichi Sugimoto, Kazuhiro Sakamoto, Takashi Tsuchiya, Takao Takahashi, Hiroki Ohge, Toshihiko Sato, Masataka Taguri, Satoshi Morita & Sotaro Sadahiro
Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
International Journal of Colorectal Disease. 31 October 2023. DOI:https://doi.org/10.1007/s00384-023-04559-7
[JFMC46-1201]
2022年
M. Kanai, T. Kawaguchi, M. Kotaka, D. Manaka, J. Hasegawa, A. Takagane, Y. Munemoto, T. Kato, T. Eto, T. Touyama, T. Matsui, K. Shinozaki, S. Matsumoto, T. Mizushima, M. Mori, J. Sakamoto, A. Ohtsu, T. Yoshino, S. Saji, F. Matsuda.
Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine- induced toxicity in an Asian population
Cancer Med. 2022 Dec 16. DOI:https://doi.org/10.1002/cam4.5541
[JFMC41-1001-C2, JFMC47-1202-C3]
S. Sadahiro, K. Sakamoto, T. Tsuchiya, T. Takahashi, H. Ohge, T. Sato, K. Kondo, Y. Ogata, H. Baba, M. Itabashi, M. Ikeda, M. Hamada, K. Maeda, H. Masuko, K. Takahashi, J. Sakamoto, M. Kusano, I. Hyodo, M. Taguri & S. Morita.
Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201）
BMC Cancer. 2022 Feb 15. DOI:https://doi.org/10.1186/s12885-022-09267-z
[JFMC46-1201]
H. Shibahara, T. Shiroiwa, M. Ishiguro, M. Nakamura, J. Hasegawa, S. Yamaguchi, Y. Masuda, J. Sakamoto, N. Tomita & T. Fukuda.
Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
Eur J Health Econ. 2022 Jan 24. DOI:https://doi.org/10.1007/s10198-021-01418-6
[JFMC37-0801]
2021年
Y. Tanaka, H. Takechi, Y. Nakashima, H. Nagano, T. Ueno, K. Tomizuka, S. Morita,Y. Emi, Y. Hamai, J. Hihara, H. Saeki, E. Oki, C. Kunisaki, E. Otsuji, H. Baba1, H.Matsubara, Y. Maehara, Y. Kitagawa, K. Yoshida.
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial－EPOC 2 (JFMC49-1601-C5)
ESMO Open. 2021 Oct 06. DOI:https://doi.org/10.1016/j.esmoop.2021.100277
[JFMC49-1601-C5]
M. Kanai, T. Kawaguchi, M. Kotaka, D. Manaka, J. Hasegawa, A. Takagane, Y.Munemoto, T. Kato, T. Eto, T. Touyama, T. Matsui, K. Shinozaki, S. Matsumoto, T.Mizushima, M. Mori, J. Sakamoto, A. Ohtsu, T. Yoshino, S. Saji, F. Matsuda.
Large-Scale Prospective Genome-Wide Association Study of Oxaliplatin in Stage II/III Colon Cancer and Neuropathy
Annals of Oncology. 2021 Aug 11. DOI:https://doi.org/10.1016/j.annonc.2021.08.1745
[JFMC41-1001-C2, JFMC47-1202-C3]
T. Takahashi, K. Yamazaki, E. Oki, M. Shiozawa, K. Mitsugi, A. Makiyama, M. Nakamura, H. Ojima, Y. Kagawa, N. Matsuhashi, H. Okuda, M. Asayama, Y. Yuasa, Y. Shimada, D. Manaka, J. Watanabe, K. Oba, T. Yoshino, K. Yoshida & Y. Maehara.
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
ESMO Open. 2021 Mar 19. DOI:https://doi.org/10.1016/j.esmoop.2021.100093
[JFMC51-1702-C7]
2020年
K. Yamazaki, T. Yamanaka, M. Shiozawa, D. Manaka, M. Kotaka, M. Gamoh, A. Shiomi, A. Makiyama, Y. Munemoto, T. Rikiyama, M. Fukunaga, T. Ueki, K. Shitara, H. Shinkai, N. Tanida, E. Oki, E. Sunami,A. Ohtsu, Y. Maehara & T. Yoshino
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
Annals of Oncology. 2020 Oct 25. DOI:https://doi.org/10.1016/j.annonc.2020.10.480
[JFMC48-1301-C4]
2019年
Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M.
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer The ACHIEVE Phase 3 Randomized Clinical Trial
JAMA Oncol. 2019;5(11):1574-1581. doi:10.1001/jamaoncol.2019.2572
[JFMC47-1202-C3]
Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A.
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3?year follow?up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Cancer Chemotherapy and Pharmacology.2019 Sep 23. doi.org/10.1007/s00280-019-03957-5.
[JFMC41-1001-C2]
Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Sato Y, Maehara Y, Kanematsu T, Kitajima M.
Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials.
Surgery Today. 2019 Feb 25. doi: 10.1007/s00595-019-01787-9. [Epub ahead of print]
doi:10.1007/s00595-019-01787-9.
[JFMC39-0902, JFMC40-1001, JFMC42-1002]
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.
ESMO Open 2019 Feb 27;4(1):e000476.
doi:10.1136/esmoopen-2018-000476.
[JFMC34-0601]
Tomita N, Kunieda K, Maeda A, Hamada C, Yamanaka T, Sato T, Yoshida K, Boku N, Nezu R, Yamaguchi S, Mishima H, Sadahiro S, Muro K, Ishiguro M, Sakamoto J, Saji S, Maehara Y.
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
British Journal of Cancer 120, 689-696 (2019).
doi:org/10.1038/s41416-019-0410-0
[JFMC37-0801]
2018年
Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M, Maeda H, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Dis Colon Rectum. 2018 Jul;61(7):803-808. doi: 10.1097/DCR.0000000000001002.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.
ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018.
[JFMC47-1202-C3]
Kanda M , Oba K, Aoyama T , Kashiwabara K , Mayanagi S , Maeda H , Honda M , Hamada C , Sadahiro S , Sakamoto J, Saji S , Yoshikawa T.
Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials
Dis Colon Rectum. 2018 Apr;61(4):461-471. doi: 10.1097/DCR.0000000000001022.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.
[JFMC34-0601]
2017年
Maeda H, Kashiwabara K , Aoyama T, Oba K , Honda M, Mayanagi S , Kanda M , Hamada C, Sadahiro S, Sakamoto J , Saji S , Yoshikawa T.
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.
J Cancer 2017 Oct 23;8(19):4057-4064. doi: 10.7150/jca.21365. eCollection 2017.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Honda M , Oba K , Akiyoshi T , Maeda H , Kashiwabara K , Kanda M , Mayanagi S , Aoyama T , Hamada C, Sadahiro S , Fukunaga Y, Ueno M , Sakamoto J , Saji S , Yoshikawa T.
Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials.
Oncotarget. 2017 Oct 12;8(58):99150-99160. doi: 10.18632/oncotarget.21845. eCollection 2017 Nov 17.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S.
Randomized phase III trial comparing surgery alone to UFT?+?PSK for stage II rectal cancer (JFMC38 trial).
Cancer Chemother Pharmacol. 2017 Nov 1. doi: 10.1007/s00280-017-3466-7. [Epub ahead of print]
[JFMC38-0901]
Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J, Saji S, Yoshikawa T.
Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.
Cancer Med. 2017 Sep 25. doi: 10.1002/cam4.1208. [Epub ahead of print]
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.
Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials.
Cancer Med. 2017 Jul;6(7):1573-1580. doi: 10.1002/cam4.1126. Epub 2017 Jun 22.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K.
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Int J Clin Oncol. 2017 Jun 30. doi: 10.1007/s10147-017-1157-3. [Epub ahead of print]
[JFMC43-1003]
Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N.
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Int J Clin Oncol. 2017 Jan 11. doi: 10.1007/s10147-016-1083-9. [Epub ahead of print]
[JFMC37-0801]
2016年
Aoyama T, Oba K, Hamada C, Sadahiro S, Honda M, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.
Comparison of clinic pathological characters and survival between right-and left-side colon cancer.
Ann. Caner Res. Ther. Vol. 24, No.2, pp.62-63, 2016.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Maeda H, Oba K, Hamada C, Sadahiro S, Aoyama T, Honda M, Mayanagi S, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.
Hazard rate of tumor recurrence over time: a pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese Foundation for Multidisciplinary Treatment of Cancer（JFMC）.
Ann. Caner Res. Ther. Vol. 24, No.2, pp.60-61, 2016.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Mayanagi S, Oba K, Hamada C, Sadahiro S, Kanda M, Maeda H, Aoyama T, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.
Risk factors associated with recurrence by peritoneal dissemination or paraaortic lymph node metastasis after curative surgery in patients with colorectal cancer.
Ann. Caner Res. Ther. Vol. 24, No.2, pp.58-59, 2016.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Honda M, Oba K, Hamada C, Sadahiro S, Mayanagi S, Kanda M, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.
Prognostic Nomogram for Colorectal Cancer after Radical Resection in Japanese Population.
Ann. Caner Res. Ther. Vol. 24, No.2, pp.56-57, 2016.
[JFMC07-8601, JFMC15-8901, JFMC33-0502]
Aoyama T, Oba K, Hamada C, Sadahiro S, Honda M, Mayanagi S, Kanda M, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T.
The relation between postoperative surgical complications and colorectal cancer survival.
Ann. Caner Res. Ther. Vol. 24, No.2, pp.54-55, 2016.
[JFMC7-8601, JFMC15-8901, JFMC33-0502]
Kanda M, Oba K, Maeda H, Aoyama T, Honda M, Kashiwabara K, Sakamoto J, Sadahiro S, Saji S, Hamada C, Yoshikawa T.
Clinical features of colorectal mucinous and poorly differentiated adenocarcinomas; study concept of a propensity score analysis in a pooled data of 5530 patients.
Ann. Caner Res. Ther. Vol. 24, No.2, pp.52-53, 2016.
[JFMC7-8601, JFMC15-8901, JFMC33-0502]
Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, Nishida Y, Iwasa S, Miwa H, Masuishi T, Boku N, Yamada Y, Kodera Y, Yoshida K, Morita S, Sakamoto J, Saji S, Kitagawa Y.
Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naive patients with HER2-positive, previously treated, advanced or recurrent gastric cancer (JFMC45-1102).
Int J Cancer. 2016 Oct 6. doi: 10.1002/ijc.30383. [Epub ahead of print]
[JFMC45-1102]
Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M.
Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
Eur J Cancer. 2016 Sep;65:164-71. doi: 10.1016/j.ejca.2016.06.012. Epub 2016 Aug 5.
[JFMC36-0701]
Kusano M, Honda M, Okabayashi K, Akimaru K, Kino S, Tsuji Y, Watanabe M, Suzuki S, Yoshikawa T, Sakamoto J, Oba K, Saji S.
Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003.
J Can Res Ther. 28-Jul-2016. (Epub ahead of print)
[JFMC29-0003]
Oki E, Murata A, Yoshida K, Maeda K, Ikejiri K, Munemoto Y, Sasaki K, Matsuda C, Kotake M, Suenaga T, Matsuda H, Emi Y, Kakeji Y, Baba H, Hamada C, Saji S, Maehara Y.
A Randomized Phase III Trial Comparing S-1 Versus UFT as Adjuvant Chemotherapy for Stage II/III Rectal Cancer (JFMC35-C1: ACTS-RC).
Ann Oncol. 2016 Jul;27(7):1266-72. doi: 10.1093/annonc/mdw162. Epub 2016 Apr 7.
[JFMC35-C1]
Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S.
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).
J Cancer Ther Res. 2016 Mar. (Ahead of Print)
[JFMC32-0501]
Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F.
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Ann Oncol. 2016 Jun;27(6):1143-8. doi: 10.1093/annonc/mdw074. Epub 2016 Feb 18.
[JFMC41-1001-C2]
2015年
Sadahiro S, Tsuchiya T, Sasaki K, Kondo K, Katsumata K, Nishimura G, Kakeji Y, Baba H, Sato S, Koda K, Yamaguchi Y, Morita T, Matsuoka J, Usuki H, Hamada C, Kodaira S.
Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
Ann Oncol. 2015 Nov;26(11):2274-80. doi: 10.1093/annonc/mdv358. Epub 2015 Sep 7.
[JFMC33-0502]
Katsuno H, Maeda K, Ohya M, Yoshioka K, Tsunoda A, Koda K, Matsuoka H, Ohge H, Morita S, Saji S, Kanematsu T, Kitajima M.
Clinical pharmacology of daikenchuto assessed by transit analysis using radiopaque markers in patients with colon cancer undergoing open surgery: a multicenter double-blind randomized placebo-controlled study (JFMC39-0902 additional study).
J Gastroenterol. 2016 Mar;51(3):222-9. doi: 10.1007/s00535-015-1100-1. Epub 2015 Jul 11.
[JFMC39-0902 additional study]
Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K.
Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Gastric Cancer. 2016 Jul;19(3):839-51. doi: 10.1007/s10120-015-0518-8. Epub 2015 Aug 12. Erratum in: Gastric Cancer. 2016 Jul;19(3):1026.
[JFMC44-1101]
Yoshikawa K, Shimada M, Wakabayashi G, Ishida K, Kaiho T, Kitagawa Y, Sakamoto J, Shiraishi N, Koeda K, Mochiki E, Saikawa Y, Yamaguchi K, Watanabe M, Morita S, Kitano S, Saji S, Kanematsu T, Kitajima M.
Effect of Daikenchuto, a Traditional Japanese Herbal Medicine, after Total Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
J Am Coll Surg. 2015 Aug;221(2):571-8. doi: 10.1016/j.jamcollsurg.2015.03.004. Epub 2015 Mar 14.
[JFMC42-1002]
Sadahiro S, Morita S, Sasaki K, Sakamoto K, Ohge H, Takahashi T, Tsuchiya T, Sato T, Kondo K, Ogata Y, Masuko H, Baba H, Maeda K, Hamada M, Itabashi M, Nishimura G, Takahashi K, Ikeda M, Taguri M, Kodaira S.
Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Clin Colorectal Cancer. 2015 Dec;14(4):277-80. doi: 10.1016/j.clcc.2015.05.004. Epub 2015 May 22
[JFMC46-1201]
Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T.
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
Cancer Chemother Pharmacol. 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16.
[JFMC41-1001-C2]
Katsuno H, Maeda K, Kaiho T, Kunieda K, Funahashi K, Sakamoto J, Kono T, Hasegawa H, Furukawa Y, Imazu Y, Morita S, Watanabe M.
Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multi-center, placebo-controlled study.(JFMC39-0902)
Jpn J Clin Oncol. 2015 Jul;45(7):650-6. doi: 10.1093/jjco/hyv056. Epub 2015 May 12.
[JFMC39-0902]
Arai Y, Aoyama T, Inaba Y, Okabe H, Ihaya T, Kichikawa K, Ohashi Y, Sakamoto J, Oba K, Saji S.
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).
Asia Pac J Clin Oncol. 2015 Mar;11(1):41-8. doi: 10.1111/ajco.12324. Epub 2015 Jan 12.
[JFMC28-0001]
2014年
Eguchi K, Honda M, Kataoka T, Mukouyama T, Tsuneto S, Sakamoto J, Oba K, Saji S.
Efficacy of corticosteroids for cancer-related fatigue: A pilot randomized placebo-controlled trial of advanced cancer patients.
Palliat Support Care. 2015 Oct;13(5):1301-8. doi: 10.1017/S1478951514001254. Epub 2014 Nov 5.
[JFMC26-9901]
Tsuchiya T, Sadahiro S, Sasaki K, Kondo K, Katsumata K, Nishimura G, Kakeji Y, Baba H, Morita T, Koda K, Sato S, Matsuoka J, Yamaguchi Y, Usuki H, Hamada C, Kodaira S, Saji S.
Safety analysis of two different regimens of uracil－tegafur plus leucovorin as adjuvant chemotherapy for high‐risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Cancer Chemother Pharmacol, 2014 Jun;73(6):1253-61. doi: 10.1007/s00280-014-2461-5. Epub 2014 Apr 18.
[JFMC33-0502]
Shimada M, Morine Y, Nagano H, Hatano E, Kaiho T, Miyazaki M, Kono T, Kamiyama T, Morita S, Sakamoto J, Kusano M, Saji S, Kanematsu T, Kitajima M.
Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III triral (JFMC40-1001).
Int J Clin Oncol. 2015 Feb;20(1):95-104. doi: 10.1007/s10147-014-0678-2. Epub 2014 Mar 6.
[JFMC40-1001]
2013年
Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Int J Clin Oncol．2014 Aug;19(4):607-13. doi: 10.1007/s10147-013-0614-x. Epub 2013 Oct 8.
[JFMC34-0601]
2012年
Gochi A, Saji S, Sakamoto J, Hirata K, Tominaga S, Yamaguchi Y, Shibata M, Kai Y, Tanemura H, Shirasaka T.
A Phase III study of combination therapy of the oral fluorinated pyrimidine compound tegafur-uracil (UFT) with low dose cisplatin compared with UFT alone in patients with locally advanced gastric cancer as postoperative adjuvant chemotherapy.
Annals of Cancer Research and Therapy, 2012;20(1):17-23.
[JFMC23-9602]
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, Sasano H, Toi M.
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.
The Breast.February 2012 Volume 21, Issue 1, Pages 40-45
[JFMC34-0601]
2011年
Hamada C, Sakamoto J, Satoh T, Sadahiro S, Mishima H, Sugihara K, Saji S, Tomita N.
Dose 1 year adjuvant chemotherapy with oral 5-FUs in colon cancer ruduce the peak of recurrence in 1 year and provide long-term OS benefit?
Jpn J Clin Oncol,2011;41(2):299-302.
[JFMC07-8601, JFMC15-8901(前後期2群)]
Komatsu Y, Takahashi Y, Kimura Y, Oda H, Tajima Y, Tamura S, Sakurai J, Wakasugi T, Tatebe S, Takahashi M, Sakata Y, Kitajima M, Sakamoto J, Saji S.
Randomized phase Ⅱ trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrant gastric carcinoma (JFMC31-0301).
Anti-Cancer Drugs.2011;22(6):576-583.
[JFMC31-0301]
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H.
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Cancer Science.2011;102(4):858-865.
[JFMC34-0601]
2010年
Nakata B, Tsuji A, Mitachi Y, Taenaka N, Kamano T, Oikawa K, Onoda N, Kambe M, Takahashi M, Shirasaka T, Morita S, Sakamoto J, Tanaka Y, Saji S, Hirakawa K.
Phase Ⅱ Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2).
Oncology.2010;79:337-342.
[JFMC27-9902 Step2]
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H.
Increased estrogen sulfatase (STS) and 17 beta-hydroxysteroid dehydrogenase type1 (17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Breast Cancer Research and Treatment.2010;120(3):639-48.
[JFMC34-0601]
2007年
Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, Oba K, Nakazato H, Saji S, Ohashi Y.
An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.
Br J Cancer.2007;96(8):1170-7.
[JFMC07-8601, JFMC15-8901]
Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, Ohashi Y, Sakamoto J, Hirakawa K.
A phase Ⅰ study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Jpn J Clin Oncol.2007;37(12):924-9.
[JFMC27-9902 Step2]
Nakata B, Sowa M, Tsuji A, Kamano T, Sasaki K, Fukunaga Y, Takahashi M, Tsujitani S, Mikami Y, Mitachi Y, Nishimura S, Araki H, Yamamitsu S, Hirakawa K, Tominaga S, Shirasaka T, Inokuchi K.
Continuous Infusion of 5-fluorouracil with Versus without Low-dose, Consecutive Administration of Cisplatin in Advenced Colorectal Cancer. A Prospecive Randomized Phase II study:
Journal of Experimental & Clinical Cancer Research.2007;26(1):51-60.
[JFMC30-0002]
2006年
Watanabe M, Kodaira S, Takahashi T, Tominaga T, Hojo K, Kato T, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M.
Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil.
Langenbeck’s Archives of Surgery.2006;391:330-337.
[JFMC15-8901(前後期2群)]
Nakata B, Tsuji A, Mitachi Y, Yamamitsu S, Hirata K, Takeuchi T, Shirasaka T, Hirakawa K.
Moderate Neutropenia with S-1 Plus Low-dose Cisplatin May Predict a More Favourable Prognosis in Advanced Gastric Cancer.
Clinical Oncology.2006;18:678-683.
[JFMC27-9902]
Watanabe M, Nishida O, Kunii Y, Kodaira S, Takahashi T, Tominaga T, Hojyo K, Kato T, Niimoto M, Kunitomo K, Isomoto H, Ohashi Y, Yasutomi M.
Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur.
International Journal of Clinical Oncology.2004;9:98-106.
[JFMC15-8901(前期3群)]
Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, Hirakawa K.
Combination Phase I Trial of a Novel Oral Fluorouracil Derivative S-1 with Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902).
Clinical Cancer Research.2004;10:1664-1669.
[JFMC27-9902]
Morita S, Ohashi Y, Hirakawa K, Nakata B; Saji S; Sakamoto J.
Clinical Trial Note；Phase Ⅰ/Ⅱ Study of Combination Therapy of Oral Fluorinated Pyrimidine Compound S-1 with Low-dose Cisplatin in Patients with Unresectable and/or Recurrent Advanced Gastric Cancer: a Novel Study Design to Evaluate Safety and Efficacy.
Japanese Journal of Clinical Oncology.2004;34(3):159-161.
[JFMC27-9902 Step2]
Takahashi Y, Sakamoto J, Takeuchi T, Mai M, Kubota T, Kitajima M, Tanigawara Y, Komatsu Y, Toge T, Saji S.
Clinical Trial Note;A Randomized Phase Ⅱ Clinical Trial of Tailored CPT-11 + S-1 vs S-1 in Patients with Advanced or Recurrent Gastric Carcinoma as the First Line Chemotherapy.
Japanese Journal of Clinical Oncology.2004;34(6):342-345.
[JFMC31-0301]
2003年
Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H; Tumor Marker Committee.
The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Gastric Cancer.2003;6:142-145.
[JFMC20-9301]
Yasumoto K, Osaki T, Watanabe Y, Kato H, Yoshimura T,(Cooperative Project No.24 Group of The Japanese Foundation For Multidisciplinary Treatment of Cancer)：
Prognostic Value of Cytokeratin-Positive Cells in the Bone Marrow and Lymph Nodes of Patients With Resected Nonsmall Cell Lung Cancer： A Multicenter Prospective Study.
The Annals OF Thoracic Surgery July 2003Volume 76, Issue 1, Pages 194-201
[JFMC24-9701]
Kondo T, Yamauchi M, Tominaga S.
Evaluation of usefulness of in-vitro drug sensitivity testing for adjuvant chemotherapy of stomach cancer.
International Journal of Clinical Oncology.2000;5:174-182.
[JFMC16-9001]
Wada M, Mizoguchi H, Kuriya S, et al.
Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon α (ROAD-IN) and a randomized comparison of interferon α maintenance in multiple myeloma: a co-operative study in Japan.
British Journal of Haematology.2000;109:805-814.
[JFMC18-9101]
Kodaira S, Kikuchi K, Yasutomi M, et al.
Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer.
International Journal of Clinical Oncology.1998;3:357-364.
[JFMC07-8601]
kazawa K, Nakamura T and Palesch Y.
Power of logrank test and Cox regression model in clinical trials with heterogeneous samples.
Statistics in Medicine.1997;16:583-597.
[その他]
Ishida K, Iizuka T, Ando N, et al.
Phase Ⅱ Study of Chemoradiotherapy for Advanced Squamous Cell Carcinoma of the Thoracic Esophagus: Nine Japanese Institutions Trial.
Japanese Journal of Clinical Oncology.1996;26(5):310-315.
[JFMC19-9201]
Tumor marker committee, Japanese Foundation for Multidisciplinary Treatment of Cancer. Sakamoto J, Nakazato H, Teramukai S, et al.
Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection.
Surgical Oncology.1996;5:133-139.
[その他]
1994年
Nagura E, Kimura K, Yamada K, et al．
Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia.
Cancer Chemotherapy and Pharmacology.1994;33:359-365.
[JFMC02-8301]
Nagura E, Kimura K, Yamada K, et al.
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
Cancer Chemotherapy and Pharmacology.1994;34:23-29.
[JFMC02-8301]
Sugimachi K, Maehara Y, Akazawa K, et al.
Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study．
Cancer Chemother Pharmacol．1994;33:366-370．
[JFMC08-8701]
Hattori T, Nakajima T, Nakazato H, et al.
Postoperative Adjuvant Immunochemotherapy with Mitomycin C, Tegafur, PSK and/or OK-432 for Gastric Cancer, with Special Reference to the Change in Stimulation Index after Gastrectomy.
The Japanese Journal of Surgery.1990;20(2):127-136.
[JFMC01-8101]
Murakami H, Hiraoka A, Nakura E, et al.
Multivariate Analysis of Factors Associated with Prognosis for Adult Acute Leukemia.
Acta Haematologica Japonica.1988;51(8):1607-1616.
[JFMC02-8301]
